Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

How Stäubli and ARxIUM collaborated on pharma automation

By Sean Whooley | January 3, 2020

ARxIUM is collaborating with Stäubli for its TX-60L UL robot to enhance the effectiveness of pharmacy operations by improving the safety and accuracy of IV admixture compounding.

The collaboration particularly aids ARxIUM’s RIVA fully automated IV compounding system used by hospital pharmacies to prepare IV syringes and bags. It is designed to address safety for the patient and the pharmacy technician by automating the preparation process.

Stäubli’s TX-60L UL robot is designed to help move products from station to station through the RIVA compounding cell as each product is processed. When combined with the RIVA, Stäubli’s product offers quick movement and allows users the flexibility to run single daily shifts, compared to some users who run RIVA for 24 hours a day, seven days a week.

Another vital aspect of RIVA highlighted by ARxIUM is the importance of strict sterile cleanliness, as the company cited the need for an automated system to fill that need. It believes that Stäubli’s TX-60L UL robot fits that bill.

ARxIUM has more than 50 TX-60L UL robots and controllers installed for RIVA compounding cells and has used RIVA machines to fill more than 8 million doses, according to a news release.

“ARxIUM takes great pride in its disciplined process of assessing a potential client’s business objectives and designing a solution that fits its specific needs and goal,” ARxIUM said in the news release. “The company applies this approach to help customers in every facet of the pharmacy market – including hospitals/health systems, government, long-term care and retail – to optimize operations and business through automated compounding, packaging and dispensing, production and workflow design, inventory control and storage and much more.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson
Fauci: J&J vaccination could resume shortly
Pfizer BioNTech
EU secures additional 100 million Pfizer-BioNTech vaccine doses
BioDelivery Sciences
President of BioDelivery Sciences on the future of chronic pain management
Catalent Biologics Madison Facility
Catalent expands biologics manufacturing facility in Wisconsin

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards